Cancer drugs and climate protection instead of nuclear waste

The development of facilities for electrochemical partitioning and accelerator-driven transmutation (P&T) is currently flourishing: the German government recently invested several million euros in Transmutex AG, a CERN spin-off dedicated to this topic. The US government has also launched NEWTON, a major programme for accelerator-driven transmutation. A current study by SPRIND, the Federal Agency for Leap Innovations, is now even looking at the conditions and effects of a plant at the site of a former German pressurised water reactor.

Could these plants be operated safely in Germany? Profitable? Efficient? Ecologically? What do they actually achieve? What job opportunities are there in this field? 

Find out in our online presentation what far-reaching economic benefits this form of P&T offers in addition to the significant reduction of already vitrified highly radioactive waste from nuclear power plants: valuable raw materials such as krypton, rhodium, ruthenium and uranium, which are required for the aerospace, automotive and solar cell industries, among others, could be recovered. The plant also enables the development of new cancer drugs through both irradiation and recycling of nuclear waste and makes a significant contribution to CO₂ reduction - both directly through process heat and geothermal energy and indirectly through the circular economy instead of mining.